Sangamo Therapeutics, Inc. (NASDAQ:SGMO) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Saturday.

A number of other equities analysts have also commented on the stock. Zacks Investment Research lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Sangamo Therapeutics in a research note on Thursday, June 22nd. ValuEngine raised shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, June 15th. Finally, Wedbush reaffirmed a “neutral” rating and issued a $4.00 price objective (down previously from $6.00) on shares of Sangamo Therapeutics in a research note on Tuesday, May 16th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the stock. Sangamo Therapeutics currently has a consensus rating of “Hold” and an average target price of $8.67.

Shares of Sangamo Therapeutics (NASDAQ:SGMO) traded up 2.98% on Friday, hitting $8.65. The company’s stock had a trading volume of 682,629 shares. The company’s market cap is $622.27 million. The stock’s 50 day moving average is $8.85 and its 200-day moving average is $5.93. Sangamo Therapeutics has a 52 week low of $2.65 and a 52 week high of $10.50.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.03. Sangamo Therapeutics had a negative net margin of 380.44% and a negative return on equity of 50.76%. The firm had revenue of $3.40 million during the quarter, compared to analyst estimates of $4.14 million. During the same quarter last year, the business posted ($0.23) EPS. The company’s revenue was down 12.8% on a year-over-year basis. On average, equities research analysts anticipate that Sangamo Therapeutics will post ($0.93) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Sangamo Therapeutics, Inc. (SGMO) Downgraded to Sell at BidaskClub” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.dailypolitical.com/2017/08/05/sangamo-therapeutics-inc-sgmo-downgraded-to-sell-at-bidaskclub.html.

In related news, VP Curt A. Herberts III sold 15,000 shares of Sangamo Therapeutics stock in a transaction on Friday, July 14th. The shares were sold at an average price of $10.00, for a total value of $150,000.00. Following the completion of the sale, the vice president now owns 35,517 shares of the company’s stock, valued at approximately $355,170. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 19,639 shares of company stock valued at $184,765 in the last three months. Company insiders own 8.10% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. acquired a new stake in Sangamo Therapeutics during the fourth quarter valued at about $179,000. Metropolitan Life Insurance Co. NY raised its stake in Sangamo Therapeutics by 1.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 49,713 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 780 shares during the last quarter. Teachers Advisors LLC raised its stake in Sangamo Therapeutics by 4.9% in the fourth quarter. Teachers Advisors LLC now owns 164,728 shares of the biopharmaceutical company’s stock valued at $502,000 after buying an additional 7,693 shares during the last quarter. Candriam Luxembourg S.C.A. raised its stake in Sangamo Therapeutics by 35.0% in the first quarter. Candriam Luxembourg S.C.A. now owns 270,000 shares of the biopharmaceutical company’s stock valued at $1,404,000 after buying an additional 70,000 shares during the last quarter. Finally, Wells Fargo & Company MN raised its stake in Sangamo Therapeutics by 13.0% in the first quarter. Wells Fargo & Company MN now owns 295,770 shares of the biopharmaceutical company’s stock valued at $1,538,000 after buying an additional 34,128 shares during the last quarter. 58.25% of the stock is owned by institutional investors and hedge funds.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.